Last updated on November 2017

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)


Brief description of study

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)

Detailed Study Description

This study is basically comparing two products that are already on the market for patients with COPD, which includes chronic bronchitis and emphysema. The study lasts for approximately 6 months and compensation is provided for your time and travel.

Clinical Study Identifier: TX9647

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Mitchell Champagne, RPh, CCRC

Midwest Chest Consultants
St. Charles, MO USA
  Connect »